FDA expands use of Salix/Progenics constipation drug Relistor
This article was originally published in Scrip
Executive Summary
The FDA has given Salix Pharmaceuticals and Progenics Pharmaceuticals the go-ahead to market their subcutaneous injectable drug Relistor (methylnaltrexone) for opioid-induced constipation (OIC) in patients with chronic non-cancer pain.